The FDA on August 18, 2021 granted accelerated approval to JEMPERLIĀ® for adult patients with MisMatch Repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. JEMPERLIĀ® is aĀ product of GlaxoSmithKline LLC.
Other Pages – Bottom Ad
Advertisement
Subscribe
